Celcuity (NASDAQ:CELC) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Celcuity (NASDAQ:CELC) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

Several other analysts have also weighed in on CELC. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Needham & Company LLC set a $95.00 price objective on Celcuity in a report on Monday, October 20th. Stifel Nicolaus assumed coverage on Celcuity in a report on Tuesday, July 1st. They set a “buy” rating and a $30.00 price objective on the stock. Leerink Partners lifted their price objective on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, July 28th. Finally, Guggenheim assumed coverage on Celcuity in a report on Monday, September 22nd. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $65.50.

Celcuity Stock Performance

CELC opened at $74.44 on Friday. The firm has a market capitalization of $3.16 billion, a P/E ratio of -21.58 and a beta of 0.70. The stock’s 50 day moving average price is $54.69 and its two-hundred day moving average price is $30.76. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 2.24. Celcuity has a 12-month low of $7.57 and a 12-month high of $83.00.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). On average, equities analysts forecast that Celcuity will post -2.62 earnings per share for the current year.

Institutional Trading of Celcuity

Several institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP boosted its stake in Celcuity by 59.0% in the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock valued at $43,046,000 after buying an additional 1,579,182 shares in the last quarter. Soleus Capital Management L.P. raised its position in Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the last quarter. Eventide Asset Management LLC raised its position in Celcuity by 9.8% in the 2nd quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after purchasing an additional 123,774 shares during the last quarter. Saturn V Capital Management LP raised its position in Celcuity by 8.4% in the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after purchasing an additional 91,843 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in Celcuity by 27.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock valued at $10,263,000 after purchasing an additional 166,324 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.